# Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors

> **NCT00094159** · PHASE1 · COMPLETED · sponsor: **Sunesis Pharmaceuticals**

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** SNS-595

## Key facts

- **NCT ID:** NCT00094159
- **Lead sponsor:** Sunesis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2007-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00094159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00094159, "Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT00094159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*